Regulus Therapeutics Crescita futura

Future criteri di controllo 0/6

Si prevede che Regulus Therapeutics aumenterà gli utili e i ricavi rispettivamente del 22.6% e 81.7% all'anno, mentre si prevede che l'EPS crescerà del 9.6% all'anno.

Informazioni chiave

22.6%

Tasso di crescita degli utili

9.6%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.4%
Tasso di crescita dei ricavi	81.7%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Good
Ultimo aggiornamento	11 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth

Sep 28

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Jun 09

Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease

May 03

Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Mar 13

Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Mar 10

Regulus Therapeutics announces closing of $19.4M private placement

Dec 08

Regulus Therapeutics EPS beats by $0.17, beats on revenue

Nov 05

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:RGLS - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	N/A	-123	-66	-59	4
12/31/2025	N/A	-85	-46	-40	6
12/31/2024	N/A	-48	-40	-34	6
9/30/2024	N/A	-42	-36	-36	N/A
6/30/2024	N/A	-35	-34	-33	N/A
3/31/2024	N/A	-31	-28	-27	N/A
12/31/2023	N/A	-30	-27	-27	N/A
9/30/2023	N/A	-29	-28	-27	N/A
6/30/2023	N/A	-28	-27	-27	N/A
3/31/2023	N/A	-29	-28	-27	N/A
12/31/2022	N/A	-28	-26	-26	N/A
9/30/2022	N/A	-29	-27	-27	N/A
6/30/2022	N/A	-30	-26	-26	N/A
3/31/2022	N/A	-29	-25	-25	N/A
12/31/2021	N/A	-28	-24	-24	N/A
9/30/2021	5	-22	-13	-13	N/A
6/30/2021	10	-15	-12	-12	N/A
3/31/2021	10	-16	-12	-12	N/A
12/31/2020	10	-16	-13	-13	N/A
9/30/2020	5	-19	-21	-21	N/A
6/30/2020	0	-23	-21	-21	N/A
3/31/2020	0	-21	-22	-21	N/A
12/31/2019	7	-19	-20	-20	N/A
9/30/2019	7	-22	-19	-19	N/A
6/30/2019	7	-27	-26	-26	N/A
3/31/2019	7	-36	-32	-32	N/A
12/31/2018	0	-49	-43	-43	N/A
9/30/2018	0	-55	-50	-50	N/A
6/30/2018	0	-60	N/A	-51	N/A
3/31/2018	0	-68	N/A	-56	N/A
12/31/2017	0	-72	N/A	-59	N/A
9/30/2017	0	-77	N/A	-63	N/A
6/30/2017	0	-81	N/A	-67	N/A
3/31/2017	1	-81	N/A	-67	N/A
12/31/2016	1	-82	N/A	-57	N/A
9/30/2016	12	-69	N/A	-59	N/A
6/30/2016	14	-63	N/A	-55	N/A
3/31/2016	17	-62	N/A	-48	N/A
12/31/2015	21	-56	N/A	-50	N/A
9/30/2015	14	-71	N/A	-44	N/A
6/30/2015	13	-67	N/A	-41	N/A
3/31/2015	10	-58	N/A	-42	N/A
12/31/2014	8	-57	N/A	-40	N/A
9/30/2014	9	-36	N/A	-37	N/A
6/30/2014	14	-29	N/A	-33	N/A
3/31/2014	18	-24	N/A	-30	N/A
12/31/2013	20	-19	N/A	-28	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che RGLS rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che RGLS rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che RGLS rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che RGLS non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che RGLS non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di RGLS è previsto essere elevato tra 3 anni

Regulus Therapeutics Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 49% to US$11.00

Price target increased to US$20.00

Price target increased to US$20.00

Price target increased to US$1.50

Consensus forecasts updated

Analysts update estimates

Recent updates

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease

Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth

New minor risk - Profitability

New minor risk - Market cap size

Price target increased by 49% to US$11.00

Regulus Therapeutics Inc. Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration

Regulus Therapeutics Inc. Announces Promotion of Rekha Garg to Chief Medical Officer

Regulus Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Regulus Therapeutics Inc., Annual General Meeting, May 16, 2024

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors

Regulus Therapeutics Inc. announced that it expects to receive $100 million in funding from a group of investors

Insufficient new directors

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1B Multiple Ascending Dose (Mad) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (Madpkd)

New major risk - Financial position

Regulus Therapeutics, Inc. Announces First Patient Dosed in Second Cohort of Phase 1b Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Appoints Preston S. Klassen to President and Head of Research and Development

Regulus Therapeutics Advances to Cohort 2 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces Resignation of Simos Simeonidis as Board Member

Regulus Therapeutics Inc. Announces Executive Changes

Insufficient new directors

Regulus Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022

Regulus Therapeutics Inc. Announces First Patient Dosed in Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces Positive Topline Safety and Pharmacokinetic Data from the Phase 1 Single-Ascending Dose (Sad) Clinical Trial of Rgls8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus surges 15% after Phase 1 data for kidney disease candidate

Price target increased to US$20.00

Regulus Therapeutics GAAP loss per share narrows

Regulus Therapeutics Inc. to Report Q2, 2022 Results on Aug 11, 2022

Insufficient new directors

Price target increased to US$20.00

Insufficient new directors

Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. Announces FDA Acceptance of Investigational New Drug Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. to Report Q1, 2022 Results on May 12, 2022

Price target increased to US$1.50

Full year 2021 earnings: EPS misses analyst expectations

Regulus Therapeutics Inc. to Report Q4, 2021 Results on Mar 10, 2022

Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome

Regulus Therapeutics Inc. Announces Successful Completion of Pre-Ind Meeting with FDA for Rgls8429

Regulus Therapeutics Inc. announced that it has received $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc.

Regulus Therapeutics Inc. announced that it expects to receive $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc.

Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Consensus forecasts updated

The Read On Regulus Therapeutics

Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021

Regulus Therapeutics Inc. to Present Additional Data from Its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program At PKD Connect 2021

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Regulus Therapeutics Inc. Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease Program

Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease

Analysts update estimates

Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Full year 2020 earnings released: US$0.45 loss per share (vs US$1.08 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

New 90-day high: US$1.94

Regulus Therapeutics Inc. Announces Completion of Enrollment in First Cohort of Phase 1B Clinical Trial of Rgls4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Appoints Alice S. Huang to the Board of Directors

New 90-day high: US$1.55

New 90-day high: US$1.21

Regulus Therapeutics announces closing of $19.4M private placement